From: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
Cohort
Number
Mean change ± SD from baseline to year 2
Pvaluea
Primary mSASSS analysis set
OASIS
169
0.9 ± 3.3
0.771
Adalimumab
307
0.8 ± 2.6
OASIS-Eligible patients
77
0.9 ± 4.1
0.744